SYNGAP-1发育性和性脑病变:体切除和神经调节的实用性
Stephanie DeGasperis1, Rajesh RamachandranNair1, Kevin C Jones1
1Division of Neurology, Department of Paediatrics, McMaster University, Hamilton, Ontario, Canada.
Epilepsy research
|August 24, 2025
概括
与SYNGAP1相关的的缓解手术如迷走神经刺激 (VNS) 和体切除 (CC) 显示出不同的结果. 体切除似乎更有效,但需要进行更大规模的研究来证实这些发现.
科学领域:
- 神经学
- 遗传学
- 病学
背景情况:
- SYNGAP1基因变异与罕见的儿童发育和性脑病 (DEE) 相关.
- 对于与SYNGAP1相关的DEE,很少报告息性外科手术,如体切除术 (CC) 和迷走神经刺激 (VNS).
研究的目的:
- 评估SYNGAP1相关DEE儿童的息性手术,特别是CC和VNS的有效性.
- 分析这些干预措施后的发作减少,反应持续时间和总体结果.
主要方法:
- 来自SynGAP研究基金公民健康数据库的非识别医疗记录的回顾性图表审查.
- 另外一个来自作者中心的病人.
- 的特征,并发症,遗传发现,EEG/神经成像和治疗反应的总结.
主要成果:
- 15名患有SYNGAP1相关的DEE的儿童接受了息性手术 (15/156,9.6%).
- 在11名儿童的神经刺激 (VNS) 显示出可变的初始发作减少 (> 50% 在63. 6%),但仅在27. 3% 观察到持续的反应.
- 在4名儿童身上进行体切除 (CC) 显示出有前途的结果,其中一人没有发作,而其他人则出现了显著的发作减少.
结论:
- 在SYNGAP1相关的DEE中,VNS的疗效是可变的,可能无法长期维持.
- 对于某些与SYNGAP1相关的DEE患者来说,体切除 (CC) 似乎是一个更有效的息选择.
- 需要更大的患者群体来验证这些初步发现并制定治疗指南.
更多相关视频
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
309
09:39Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation
Published on: June 7, 2016
10.6K
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446
01:24Epilepsy and Seizures: Overview
277
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
277
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
640
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
640